Altimmune (ALT) Competitors $3.61 -0.08 (-2.17%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.64 +0.04 (+0.97%) As of 08/1/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALT vs. EVO, SRPT, NTLA, PHVS, WVE, CVAC, CALT, PAHC, AUPH, and CDTXShould you be buying Altimmune stock or one of its competitors? The main competitors of Altimmune include Evotec (EVO), Sarepta Therapeutics (SRPT), Intellia Therapeutics (NTLA), Pharvaris (PHVS), WAVE Life Sciences (WVE), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Phibro Animal Health (PAHC), Aurinia Pharmaceuticals (AUPH), and Cidara Therapeutics (CDTX). These companies are all part of the "pharmaceutical products" industry. Altimmune vs. Its Competitors Evotec Sarepta Therapeutics Intellia Therapeutics Pharvaris WAVE Life Sciences CureVac Calliditas Therapeutics AB (publ) Phibro Animal Health Aurinia Pharmaceuticals Cidara Therapeutics Altimmune (NASDAQ:ALT) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation. Do insiders and institutionals hold more shares of ALT or EVO? 78.1% of Altimmune shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 4.1% of Altimmune shares are owned by insiders. Comparatively, 1.0% of Evotec shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is ALT or EVO more profitable? Evotec has a net margin of -26.34% compared to Altimmune's net margin of -451,200.00%. Evotec's return on equity of -21.51% beat Altimmune's return on equity.Company Net Margins Return on Equity Return on Assets Altimmune-451,200.00% -65.44% -58.43% Evotec -26.34%-21.51%-10.54% Which has stronger earnings & valuation, ALT or EVO? Altimmune has higher earnings, but lower revenue than Evotec. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAltimmune$20K14,640.36-$95.06M-$1.26-2.87Evotec$862.40M1.66-$212.18MN/AN/A Do analysts prefer ALT or EVO? Altimmune presently has a consensus price target of $18.20, indicating a potential upside of 404.16%. Evotec has a consensus price target of $5.90, indicating a potential upside of 46.77%. Given Altimmune's stronger consensus rating and higher possible upside, analysts clearly believe Altimmune is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Altimmune 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75Evotec 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more risk & volatility, ALT or EVO? Altimmune has a beta of -0.01, indicating that its share price is 101% less volatile than the S&P 500. Comparatively, Evotec has a beta of 1.67, indicating that its share price is 67% more volatile than the S&P 500. Does the media favor ALT or EVO? In the previous week, Altimmune had 3 more articles in the media than Evotec. MarketBeat recorded 4 mentions for Altimmune and 1 mentions for Evotec. Altimmune's average media sentiment score of 0.27 beat Evotec's score of 0.00 indicating that Altimmune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evotec 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAltimmune beats Evotec on 10 of the 15 factors compared between the two stocks. Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALT vs. The Competition Export to ExcelMetricAltimmuneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$299.29M$2.46B$5.48B$9.51BDividend YieldN/A1.81%4.73%4.09%P/E Ratio-2.878.9728.6723.80Price / Sales14,640.36437.63373.9066.58Price / CashN/A157.7635.4557.96Price / Book2.074.838.275.55Net Income-$95.06M$31.62M$3.24B$259.03M7 Day Performance-11.52%-5.28%-3.69%-4.59%1 Month Performance-26.33%4.38%4.33%4.46%1 Year Performance-39.83%-2.49%25.95%18.03% Altimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALTAltimmune2.2452 of 5 stars$3.61-2.2%$18.20+404.2%-40.7%$299.29M$20K-2.8750Upcoming EarningsEVOEvotec2.0865 of 5 stars$3.69-13.4%$5.93+60.8%-13.2%$1.31B$862.40M0.004,827News CoverageHigh Trading VolumeSRPTSarepta Therapeutics4.71 of 5 stars$13.32-5.4%$53.50+301.7%-89.0%$1.31B$2.23B-4.951,372Trending NewsUpcoming EarningsAnalyst ForecastOptions VolumeHigh Trading VolumeNTLAIntellia Therapeutics4.501 of 5 stars$12.63+4.7%$33.37+164.2%-54.3%$1.31B$57.88M-2.41600News CoverageUpcoming EarningsGap DownHigh Trading VolumePHVSPharvaris1.7483 of 5 stars$23.84+2.5%$36.20+51.8%+25.5%$1.25BN/A-7.9230Positive NewsWVEWAVE Life Sciences4.7497 of 5 stars$7.87-5.6%$20.15+156.1%+40.1%$1.22B$108.30M-9.37240News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionCVACCureVac4.4438 of 5 stars$5.40+0.2%$6.83+26.5%+51.1%$1.21B$579.18M5.87880News CoveragePositive NewsCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180PAHCPhibro Animal Health4.1332 of 5 stars$29.14-0.9%$24.40-16.3%+41.1%$1.18B$1.02B37.361,940Positive NewsDividend AnnouncementAUPHAurinia Pharmaceuticals2.3298 of 5 stars$8.62-0.1%$11.50+33.4%+87.0%$1.16B$235.13M30.79300Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionCDTXCidara Therapeutics3.1487 of 5 stars$57.05-4.9%$57.29+0.4%+389.1%$1.15B$1.27M-1.9490Upcoming EarningsHigh Trading Volume Related Companies and Tools Related Companies Evotec Alternatives Sarepta Therapeutics Alternatives Intellia Therapeutics Alternatives Pharvaris Alternatives WAVE Life Sciences Alternatives CureVac Alternatives Calliditas Therapeutics AB (publ) Alternatives Phibro Animal Health Alternatives Aurinia Pharmaceuticals Alternatives Cidara Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALT) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
